AI summary · may contain errors
Neoadjuvant camrelizumab plus apatinib in resectable stage II–IVA HNSCC achieved an overall major pathological response rate of 29.3% (12/41) with low grade ≥3 toxicity (2.4%).
Moving in Journal of Investigative Dermatology, JAMA Dermatology, Clinical Cancer Research, bioRxiv, Journal for ImmunoTherapy of Cancer, EMBO Molecular Medicine, European Urology and Journal of Clinical Investigation.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
Neoadjuvant camrelizumab plus apatinib in resectable stage II–IVA HNSCC achieved an overall major pathological response rate of 29.3% (12/41) with low grade ≥3 toxicity (2.4%).
AI summary · may contain errors
Morphea and systemic sclerosis are linked to higher overall cancer incidence than the general population, with SIRs of 1.24 and 1.37, respectively.
AI summary · may contain errors
Inducible N-MYC expression in mouse BCC models promotes an NICD low;K10 low;Ki67+ undifferentiated, transit-amplifying progenitor-like state, and N-Myc ablation blunts tumor formation.
AI summary · may contain errors
In the NEO-CESQ phase II trial of perioperative cemiplimab for stage III–IV resectable cutaneous squamous cell carcinoma, major pathological response occurred in 11 of 25 patients (44%).
AI summary · may contain errors
Ruxolitinib exposure is linked to aggressive cutaneous squamous cell carcinoma (cSCC) in pharmacovigilance and a large cohort, with mechanistic support from JAK2-driven MAPK activation.
AI summary · may contain errors
Neoadjuvant nivolumab plus carboplatin and paclitaxel in locally advanced, resectable head and neck squamous cell carcinoma improves pathologic response rates versus chemotherapy or immunotherapy alone.
AI summary · may contain errors
SPOT-Mut predicts TP53 mutations from cutaneous SCC spatial transcriptomics with precision and recall exceeding 95% in most cancer types, enabling localization of subclonal alterations.
AI summary · may contain errors
Neoadjuvant cemiplimab in resectable stage II to IV cutaneous squamous cell carcinoma shows durable 54-month event-free survival of 76.2%, with no late recurrences.
AI summary · may contain errors
Retifanlimab plus carboplatin and paclitaxel improved progression-free survival in 308 treatment-naïve patients with unresectable or metastatic squamous cell carcinoma of the anal canal, HR 0.63.
AI summary · may contain errors
Triple-exposure tumors (alcohol, tobacco, and HPV) show coordinated promoter methylation changes across seven interferon-γ–PD-L1 signaling genes, including CD274, with region overlap at PDCD1, MIR34AHG, and JAK1.
Journals this month
Topics moving, week to 17 Nov 2026
By field